The Lancet Infectious Diseases Publishes Phase 3 Study Results Confirming Superior Rate of Sustained Clinical Response of DIFICIDÂ® (fidaxomicin) Tablets Compared to Oral Vancomycin in Adult Patients with Clostridium diffici